NIS mediates iodide uptake in the female reproductive tract and is a poor prognostic factor in ovarian cancer

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 7, 2014, Pages

  Riesco Eizaguirre, Garcilaso ^a,b   Leoni, Suzana Garcia ^a   Mendiola, Marta ^b   Estevez Cebrero, Maria Angeles ^a   Gallego, Marta Ines ^c   Redondo, Andrés ^b   Hardisson, David ^b   Santisteban, Pilar ^a   De La Vieja, Antonio ^d  

^a CSIC   (Spain)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d Unidad Funcional de Investigación en Enfermedades Crónicas   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR ALPHA; IODIDE; RADIOACTIVE IODINE; SODIUM IODIDE SYMPORTER; TRANSCRIPTION FACTOR PAX8;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER GRADING; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CONTROLLED STUDY; ESTRUS CYCLE; FEMALE; FEMALE GENITAL SYSTEM; HUMAN; IMMUNOBLOTTING; IMMUNOCHEMISTRY; IN VIVO STUDY; NONHUMAN; OVARY CANCER; OVULATION; PRIORITY JOURNAL; RAT; REGULATORY MECHANISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UTERINE TUBE;

ADULT; ANIMALS; FEMALE; GENITALIA, FEMALE; HELA CELLS; HUMANS; IODINE; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PROGNOSIS; RATS; RATS, WISTAR; SYMPORTERS;

EID: 84904045314     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-4249     Document Type: Article

References (40)

1. Dohan O, De la Vieja A, Paroder V, eta l. The sodium/iodide Symporter (NIS): characterization, regulation, and medical significance. Endocr Rev. 2003;24:48-77. (Pubitemid 36223279)
2. Kogai T, Brent GA. The sodium iodide symporter (NIS): regulation and approaches to targeting for cancer therapeutics. Pharmacol Ther. 2012;135:355-370.
3. Riesco-Eizaguirre G, Santisteban P. A perspective view of sodium iodide symporter research and its clinical implications. Eur J Endocrinol. 2006;155:495-512. (Pubitemid 44608424)
4. De La Vieja A, Dohan O, Levy O, Carrasco N. Molecular analysis of the sodium/iodide symporter: impact on thyroid and extrathyroid pathophysiology. Physiol Rev. 2000;80:1083-1105. (Pubitemid 30452012)
5. Taki K, Kogai T, Kanamoto Y, Hershman JM, Brent GA. A thyroid-specific far-upstream enhancer in the human sodium/iodide symporter gene requires Pax-8 binding and cyclic adenosine 3′,5′-monophosphate response element-like sequence binding proteins for full activity and is differentially regulated in normal and thyroid cancer cells. Mol Endocrinol. 2002;16:2266-2282. (Pubitemid 35155539)
6. Ohno M, Zannini M, Levy O, Carrasco N, di Lauro R. The paired-domain transcription factor Pax8 binds to the upstream enhancer of the rat sodium/iodide symporter gene and participates in both thyroid-specific and cyclic-AMP-dependent transcription. Mol Cell Biol. 1999;19:2051-2060. (Pubitemid 29098263)
7. Tazebay UH, Wapnir IL, Levy O, et al. The mammary gland iodide transporter is expressed during lactation and in breast cancer. Nat Med. 2000;6:871-878. (Pubitemid 30644744)
8. Wapnir IL, van de Rijn M, Nowels K, et al. Immunohistochemical profile of the sodium/iodide symporter in thyroid, breast, and other carcinomas using high density tissue microarrays and conventional sections. J Clin Endocrinol Metab. 2003;88:1880-1888. (Pubitemid 36623418)
9. Lacoste C, Herve J, Bou Nader M, et al. Iodide transporter NIS regulates cancer cell motility and invasiveness by interacting with the Rho guanine nucleotide exchange factor LARG. Cancer Res. 2012;72:5505-5515.
10. Hingorani M, Spitzweg C, Vassaux G, Newbold K, et al. The biology of the sodium iodide symporter and its potential for targeted gene delivery. Curr Cancer Drug Targets. 2010;10:242-267.
11. Riesco-Eizaguirre G, De la Vieja A, Rodriguez I, et al. Telomerase-driven expression of the sodium iodide symporter (NIS) for in vivo radioiodide treatment of cancer: a new broad-spectrum NIS-mediated antitumor approach. J Clin Endocrinol Metab. 2011;96:E1435-E1443.
12. Willhauck MJ, Samani BR, Wolf I, et al. The potential of 211Astatine for NIS-mediated radionuclide therapy in prostate cancer. Eur J Nucl Med Mol Imaging. 2008;35:1272-1281.
13. Smanik PA, Ryu KY, Theil KS, Mazzaferri EL, Jhiang SM. Expression, exon-intron organization, and chromosome mapping of the human sodium iodide symporter. Endocrinology. 1997;138:3555-3558. (Pubitemid 27345712)
14. Bray F, Loos AH, Tognazzo S, LA Vecchia C. Ovarian cancer in Europe: cross-sectional trends in incidence and mortality in 28 countries, 1953-2000. Int J Cancer. 2005;113:977-990. (Pubitemid 40096878)
15. Bast RC Jr, Hennessy B, Mills GB. The biology of ovarian cancer: new opportunities for translation. Nature reviews. Cancer. 2009;9:415-428.
16. Hardisson D, Moreno-Bueno G, Sanchez L, et al. Tissue microarray immunohistochemical expression analysis of mismatch repair (hMLH1 and hMSH2 genes) in endometrial carcinoma and atypical endometrial hyperplasia: relationship with microsatellite instability. Mod Pathol. 2003;16:1148-1158. (Pubitemid 37414210)
17. Garcia-Zaragoza E, Perez-Tavarez R, Ballester A, et al. Intraepithelial paracrine Hedgehog signaling induces the expansion of ciliated cells that express diverse progenitor cell markers in the basal epithelium of the mouse mammary gland. Dev Biol. 2012;372:28-44.
18. Wilbur DC, Willis J, Mooney RA, Fallon MA, Moynes R, di Sant'Agnese PA. Estrogen and progesterone receptor detection in archival formalin-fixed, paraffin-embedded tissue from breast carcinoma: a comparison of immunohistochemistry with the dextrancoated charcoal assay. Mod Pathol. 1992;5:79-84.
19. Kinsel LB, Szabo E, Greene GL, Konrath J, Leight GS, McCarty KS Jr. Immunocytochemical analysis of estrogen receptors as a predictor of prognosis in breast cancer patients: comparison with quantitative biochemical methods. Cancer Res. 1989;49:1052-1056. (Pubitemid 19064367)
20. Klintman M, Bendahl PO, Grabau D, Lovgren K, Malmstrom P, Ferno M. The prognostic value of Ki67 is dependent on estrogen receptor status and histological grade in premenopausal patients with node-negative breast cancer. Mod Pathol. 2010;23:251-259.
21. Leoni SG, Kimura ET, Santisteban P, De la Vieja A. Regulation of thyroid oxidative state by thioredoxin reductase has a crucial role in thyroid responses to iodide excess. Mol Endocrinol. 2011;25:1924-1935.
22. De la Vieja A, Ginter CS, Carrasco N. Molecular analysis of a congenital iodide transport defect: G543E impairs maturation and trafficking of the Na+/I- symporter. Mol Endocrinol. 2005;19:2847-2858. (Pubitemid 41577254)
23. Chen CA, Okayama H. Calcium phosphate-mediated gene transfer: a highly efficient transfection system for stably transforming cells with plasmid DNA. Biotechniques. 1988;6:632-638.
24. Vilain C, Rydlewski C, Duprez L, et al. Autosomal dominant transmission of congenital thyroid hypoplasia due to loss-of-function mutation of PAX8. J Clin Endocrinol Metab. 2001;86:234-238. (Pubitemid 32109801)
25. Belandia B, Orford RL, Hurst HC, Parker MG. Targeting of SWI/SNF chromatin remodelling complexes to estrogen-responsive genes. EMBO J. 2002;21:4094-4103. (Pubitemid 34857441)
26. Smith MS, Freeman ME, Neill JD. The control of progesterone secretion during the estrous cycle and early pseudopregnancy in the rat: prolactin, gonadotropin and steroid levels associated with rescue of the corpus luteum of pseudopregnancy. Endocrinology. 1975;96:219-226.
27. Alotaibi H, Yaman EC, Demirpence E, Tazebay UH. Unliganded estrogen receptor-α activates transcription of the mammary gland Na+/I- symporter gene. Biochem Biophys Res Commun. 2006;345:1487-1496. (Pubitemid 43817900)
28. Majerus PM, Courtois PA. Susceptibility of Candida albicans to peroxidase-catalyzed oxidation products of thiocyanate, iodide and bromide. J Biol Bucc. 1992;20:241-245.
29. Venturi S, Venturi M. Iodine in evolution of salivary glands and in oral health. Nutr Health. 2009;20:119-134.
30. Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19:1167-1214.
31. Raymond JP, Izembart M, Marliac V, Dagousset F, Merceron RE, Vulpillat M, Vallee G. Temporary ovarian failure in thyroid cancer patients after thyroid remnant ablation with radioactive iodine. J Clin Endocrinol Metab. 1989;69:186-190. (Pubitemid 19172445)
32. Ceccarelli C, Bencivelli W, Vitti P, Grasso L, Pinchera A. Outcome of radioiodine-131 therapy in hyperfunctioning thyroid nodules: a 20 years' retrospective study. Clin Endocrinol (Oxf). 2005;62:331-335. (Pubitemid 40380414)
33. Pacini F, Schlumberger M, Dralle H, et al. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol. 2006;154:787-803. (Pubitemid 43997716)
34. Spitzweg C, Morris JC. Gene therapy for thyroid cancer: current status and future prospects. Thyroid. 2004;14:424-434. (Pubitemid 38868761)
35. Banerjee S, Kaye SB. New strategies in the treatment of ovarian cancer: current clinical perspectives and future potential. Clin Cancer Res. 2013;19:961-968.
36. Williams D. Radiation carcinogenesis: lessons from Chernobyl. Oncogene. 2008;27(suppl 2):S9-S18.
37. Kobel M, Kalloger SE, Boyd N, et al. Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med. 2008;5:e232.
38. Bowen NJ, Logani S, Dickerson EB, et al. Emerging roles for PAX8 in ovarian cancer and endosalpingeal development. Gynecol Oncol. 2007;104:331-337. (Pubitemid 46135661)
39. Kurman RJ. Origin and molecular pathogenesis of ovarian high-grade serous carcinoma. Ann Oncol 2013;24(suppl 10):x16-x21.
40. Cheung HW, Cowley GS, Weir BA, et al. Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer. Proc Natl Acad Sci USA. 2011;108:12372-12377.